Exploiting Potential Molecular Compounds for Treating Testicular Seminoma by Targeting Immune Related Genes

Yankang Cui, Xiaodie Zhou, Jing Zhang, Bo Fang, Jingping Ge, Hao Tang, Bianjiang Liu, Haowei He, Feng Xu, Xue‐Jun ShangResearch Square 2024 · DOI

Introduction

Testicular germ cell tumors (TGCTs) represent the most prevalent solid malignancy among young men, with seminoma being the most common histological subtype. While cisplatin-based chemotherapy is highly effective for most patients, approximately 30% of those with advanced disease develop resistance. For this subset, the clinical outlook is bleak: salvage therapies are often toxic and aggressive, yet the risk of cancer-related mortality remains as high as 50%. Currently, there is a critical lack of alternative therapeutic modalities beyond standard chemotherapy. This study addresses this gap by identifying immune-related biomarkers that predict patient outcomes and discovering targeted molecular compounds to improve survival.

Methods

The researchers employed a multi-stage "dry-lab to wet-lab" approach. Initially, transcriptomic data from the TCGA-TGCT and GTEx databases were analyzed to identify differentially expressed immune-related genes (IRGs). Weighted Gene Co-expression Network Analysis (WGCNA) was used to identify gene modules, followed by LASSO and Cox regression analyses to construct a three-gene prognostic signature comprising CTLA4, SNX17, and TMX1.

The signature's predictive power was validated using external cohorts (GSE99420 and GSE197778) and local clinical samples (38 seminoma cases). The immune landscape was mapped using CIBERSORT and TIDE to assess immune cell infiltration and potential responsiveness to immunotherapy. To identify therapeutic candidates, the team performed in silico drug screening using molecular docking (MOE software) and molecular dynamics simulations (Gromacs) against the three signature proteins. Finally, the efficacy of identified compounds—Rutin, ICG-001, and Doxorubicin—was validated through in vitro assays using the Tcam-2 cell line and in vivo nude mice xenograft models.

Key Insights and Results

The three-gene Immune-Related Prognostic Signature (IRPS) demonstrated exceptional predictive accuracy. The Area Under the Curve (AUC) for predicting 5-year progression-free survival (PFS) reached 0.943, significantly outperforming traditional clinical markers such as T-stage and lymphovascular invasion. Decision Curve Analysis (DCA) further confirmed that integrating the IRPS with clinical factors provides the highest net benefit for clinical decision-making.

The study revealed distinct roles for the signature genes:

  • CTLA4 was identified as a protective factor in this context; higher expression correlated with improved survival and increased infiltration of gamma delta T cells, suggesting a complex role in the seminoma immune microenvironment.
  • SNX17 and TMX1 acted as risk factors, where their upregulation was associated with memory B-cell exhaustion and higher relapse rates.

Crucially, the drug screening identified specific modulators that could potentially reverse these risk profiles:

  • Rutin (an antioxidant) was found to upregulate the protective CTLA4.
  • ICG-001 and Doxorubicin were shown to downregulate the risk-associated SNX17 and TMX1, respectively.

Experimental validation confirmed that these compounds significantly inhibit the proliferation, migration, and invasion of seminoma cells in vitro and result in significantly smaller tumor masses in animal models compared to control groups. Molecular dynamics simulations confirmed that these compounds form stable, low-energy bonds with their target proteins, suggesting high specificity.

Conclusion and Future Directions

This study establishes a robust three-gene immune-related signature that accurately predicts prognosis and immunotherapy response in testicular seminoma. By identifying Rutin, ICG-001, and Doxorubicin as potential targeted therapies, the research provides a promising foundation for treating cisplatin-resistant cases.

While the results are promising, the authors acknowledge that the local validation cohort was relatively small and that further testing across a broader range of seminoma models is needed. Additionally, while Doxorubicin is a known chemotherapy agent, the use of Rutin and ICG-001 specifically for seminoma requires rigorous clinical trials to determine optimal dosing and safety in human patients. Nonetheless, these findings offer a significant step toward personalized medicine for seminoma patients.

Summary updated

Abstract

<title>Abstract</title> Background In cases of advanced seminoma, up to 30% of patients may manifest cisplatin resistance, necessitating aggressive salvage therapy, with a consequent 50% risk of mortality attributable to cancer. Nevertheless, beyond chemotherapy, no further therapeutic modalities have been implemented for these patients. Methods The study commenced with the identification of differentially expressed immune-related genes, which were subsequently subjected to clustering using WGCNA. Prognostic signature construction ensued through the execution of univariable Cox regression, lasso regression, and multivariable Cox regression analyses. To validate the prognostic signature, the TCGA-TGCT and GSE99420 cohorts were employed, with assessments conducted via PFS, C-index, DCA, and ROC analyses. Subsequent exploration of the immune landscape and potential immunotherapeutic applications was undertaken through Cibersort and TIDE analyses. Molecular docking and dynamics simulation techniques were then employed for screening potential molecular compounds. Validation of these findings was pursued through in vitro and vivo assays. Results CTLA4, SNX17, and TMX1 were selected to construct the signature. Patients in the high-risk group exhibited diminished progression-free survival rates. The AUC for predicting survival at 1, 3, and 5 years was 0.802, 0.899, and 0.943, respectively, surpassing those of other risk factors, such as lymphovascular invasion and T stage. The C-index for the risk score was 0.838. Decision curve analysis (DCA) suggests that incorporating lymphovascular invasion and the risk score yields the most favorable decision-making outcomes for patients. Moreover, individuals classified as high-risk may derive greater benefit from immunotherapy. Molecular compounds including Rutin, ICG-001, and Doxorubicin can selectively target CTLA4, SNX17, and TMX1, respectively, thereby inhibiting the proliferation and invasive capabilities of seminoma tumor cells in vitro and vivo. Conclusion The signature initially constructed based on immune-related genes shows promise for predicting outcomes and assessing the efficacy of immunotherapy in seminoma patients. Rutin, ICG-001, and Doxorubicin have demonstrated potential to target these signature genes and inhibit tumor cell viability.
BibTeX
@inproceedings{cui2024exploiting,
  author = {Yankang Cui and Xiaodie Zhou and Jing Zhang and Bo Fang and Jingping Ge and Hao Tang and Bianjiang Liu and Haowei He and Feng Xu and Xue‐Jun Shang},
  title = {{Exploiting Potential Molecular Compounds for Treating Testicular Seminoma by Targeting Immune Related Genes}},
  booktitle = {Research Square},
  year = {2024},
  doi = {10.21203/rs.3.rs-4988208/v1},
}
Figure